Pharma firms face multi-million Brexit bill, MPs warned



Pharmaceutical companies face a multi-million euro bill in regulatory costs regardless of whether the UK reaches a ‘soft’ or ‘hard’ Brexit deal with the European Union, industry leaders warned on Tuesday (19 December)

Our working assumption is for between £60-£70 million in contingency planning costs in the scenario of a ‘no deal’ over the next three to four years,” GlaxoSmithKline’s Global Affairs President Phil Thompson told MPs on the House of Commons Health select committee.

CONTINUE READING ON www.euractiv.com


                   

Related News